Chinese covid-19 specific drug "seed candidate" phase III clinical trial has been unblinded


"Compared with the new crown antibody drugs that have been approved for emergency use in Europe and the United States, we are the only one that has conducted and obtained data on the therapeutic effect of the mutant strain of infection." Linqi Zhang, a professor at Tsinghua University School of Medicine, briefly mentioned some of the advantages of our new crown antibody drug candidate that he developed as a subject leader.

Rapid R&D progress, high data quality and good results ...... The combination of neo-crown drugs BRII-196 and BRII-198, developed by Tsinghua University, Shenzhen Third People's Hospital and Teng Sheng Bo Medicine, has obvious advantages in the global development of neo-crown potent drugs.

According to the latest news obtained by Science and Technology Daily reporter, the "seed drug" phase III clinical has been unveiled blind, the administration of the drug group after 28 days of treatment to achieve zero death, the control group of 8 cases of death, detailed results will be announced in the near future.

Internationally, the same type of antibody drug has been approved for emergency use, with the neutralizing antibody from Regenerative Elements reducing hospitalization and mortality by 70% and the neutralizing antibody from GlaxoSmithKline/Vir Biotech reducing hospitalization and mortality by 79%, but both neutralizing antibody clinical trials did not include data on mutant strains and enrolled subjects within 5-7 days of diagnosis. patients within 5-7 days of diagnosis. In contrast, BRII-196 and BRII-198, which enrolled subjects within 10 days of onset, had longer in vivo disease progression and were more difficult to treat, still yielded significant protection data of 78%.